Page 2
Triumvira steers series A up to $100m
Triumvera, co-founded by McMaster's professor Jonathan Bramson, looks to progress its solid tumour therapeutic candidate.
SiFive secures $175m series F
UC Berkeley spinout SiFive has fetched a $2.5bn valuation in a series F round that pushed its overall financing to more than $350m.
Scipher Medicine unlocks $110m round
Cowen Healthcare Investments has led a funding round for Scipher Medicine, co-founded by Harvard Medical School colleagues Joseph Loscalzo and Albert-László Barabási.
MindMaze finds way to $105m
EPFL spinout MindMaze has raised $105m from investors including AlbaCore Capital, which had supplied $125m in capital only four months ago.
Seismic Therapeutic emerges with $101m
Harvard’s serial entrepreneur Timothy Springer has formally launched his latest venture with a $101m series A round backed by GV.
Scandit captures $150m series D
Scandit has welcomed back shareholders including GV, Schneider Electric, Sony and Swisscom for a round that made the ETH Zurich spinout a unicorn.
Superpedestrian completes $125m funding journey
MIT spinout Superpedestrian has collected $125m in a series C round that attracted Sony Innovation Fund and Citi Impact Fund.
Enable Injections exercises $215m series C
Ohio Innovation Fund was among the shareholders who returned for Enable Injections’ latest round.
ImmPact Bio forges ahead with $111m
Advancing foundational research from UCLA and Migal – Galilee Research Institute, ImmPact is working on T-cell therapies for liquid and solid cancers.
Ori Biotech orchestrates series B
UCL spinout Ori Biotech has raised more than $100m in a series B round led by Novalis LifeSciences, just over a year after closing a $30m series A round.